MediciNova - Worst Pharma Stocks of 2007

Company: MediciNova
Starting stock price: $14.00
Ending stock price: $4.6
Percent Change: -67.14%

Details: MediciNova acquires small-molecule drugs from Japanese and other international pharmaceutical companies and accelerates their development. MediciNova currently has eight compounds, six in clinical development, for ten different therapeutic indications. In 2007 the company released results for two of those candidates, MN-221 for Status Asthmaticus and MN-166 for black hole formation in MS patients.

MediciNova - Worst Pharma Stocks of 2007

Suggested Articles

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.